NCT01160250Approved For Marketing不适用
A Single-Arm, Open-Label, Expanded Access Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
This is an open-label, non-comparative, multicenter, expanded access study of Vismodegib (GDC-0449) in patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC (mBCC) who are otherwise without satisfactory treatment options.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For patients with mBCC, histologic confirmation of distant BCC metastasis
- •For patients with locally advanced BCC, at least one histologically confirmed lesion 10 mm or more in diameter and written confirmation from a surgical specialist that the tumor is considered inoperable or that surgery is contraindicated
- •For patients with locally advanced BCC, radiotherapy must have been previously administered for locally advanced BCC, unless radiotherapy is contraindicated or inappropriate. For patients whose locally advanced BCC has been irradiated, disease must have progressed after radiation.
- •Patients with Gorlin syndrome may enroll in this study but must meet the criteria for locally advanced or metastatic disease listed above
- •Patients with measurable and/or non-measurable disease (as defined by RECIST) are allowed
- •Adequate organ function
- •For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 12 months after discontinuation of Vismodegib (GDC-0449)
- •For men with female partners of childbearing potential, agreement to use a latex condom, and to advise their female partner to use an additional method of contraception during the study and for 3 months after discontinuation of Vismodegib (GDC-0449)
排除标准
- •Pregnancy or lactation
- •Life expectancy < 12 weeks
- •Concurrent non-protocol-specified anti-tumor therapy
- •Completion of most recent anti-tumor therapy at least 21 days prior to initiation of treatment
- •Uncontrolled medical illnesses such as infection requiring treatment with intravenous antibiotics
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or renders the patient at high risk from treatment complications
- •Unwillingness to practice effective birth control
研究者
相似试验
已完成
2 期
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaBasal Cell CarcinomaNCT01367665Hoffmann-La Roche1,232
进行中（未招募）
不适用
safety and efficacy of pasireotide s.c. in patients with Cushing's diseaseCushing’s diseaseMedDRA version: 18.1Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 100000004860EUCTR2010-024165-44-CZovartis Pharma Services AG200
进行中（未招募）
不适用
An expanded access study of everolimus in patients with advanced neuroendocrine tumors.The study will evaluate the safety of everolimus in patients with advanced neuroendocrine tumors of gastrointestinal, lung or pancreatic origin.MedDRA version: 14.0Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023032-17-ITOVARTIS FARMA400
进行中（未招募）
1 期
An open-label, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who are intolerant of or have progressed despite any available vascular endothelial growth factor receptor tyrosine kinase inhibitor therapyPatients with metastatic carcinoma of the kidney who are intolerant of or have progressed despite any available vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy.MedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2007-005460-28-CZovartis Pharma Services AG
进行中（未招募）
不适用
An open-label, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who have progressed despite vascular endothelial growth factor receptor tyrosine kinase inhibitor therapyPatients with metastatic carcinoma of the kidney who have progressed despite vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy.MedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2007-005460-28-GRovartis Pharma Services AG1,000